Oz Azam and Carl June
June 2, 2021 11:00 AM EDTUpdated June 3, 05:22 AM
R&D

Ex­clu­sive: Carl June’s Tmu­ni­ty en­coun­ters a lethal road­block as 2 pa­tient deaths de­rail lead tri­al, raise red flag forc­ing a re­think of CAR-T for sol­id tu­mors

John Carroll

Editor & Founder

The mul­ti­fac­eted cam­paign to cre­ate a CAR-T for sol­id tu­mors has run in­to a lethal prob­lem.

In ex­clu­sive in­ter­views, Tmu­ni­ty founders Carl June and Oz …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times